These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 15863798

  • 21. The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial.
    Ghanizadeh A, Nikseresht MS, Sahraian A.
    Schizophr Res; 2013 Jun; 147(1):110-115. PubMed ID: 23583010
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity.
    Smith IG, Goulder MA, Sibutramine Clinical Study 1047 Team.
    J Fam Pract; 2001 Jun; 50(6):505-12. PubMed ID: 11407998
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial.
    McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, Johnson F, Mooradian AD.
    Arch Intern Med; 2000 Jul 24; 160(14):2185-91. PubMed ID: 10904462
    [Abstract] [Full Text] [Related]

  • 25. Effects of sibutramine treatment in obese adolescents: a randomized trial.
    Berkowitz RI, Fujioka K, Daniels SR, Hoppin AG, Owen S, Perry AC, Sothern MS, Renz CL, Pirner MA, Walch JK, Jasinsky O, Hewkin AC, Blakesley VA, Sibutramine Adolescent Study Group.
    Ann Intern Med; 2006 Jul 18; 145(2):81-90. PubMed ID: 16847290
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
    Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP, Torp-Pedersen C, Bacher HP, Shepherd GM, James WP, SCOUT Investigators.
    Diabetes Obes Metab; 2009 Mar 18; 11(3):239-50. PubMed ID: 18671798
    [Abstract] [Full Text] [Related]

  • 30. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.
    Poyurovsky M, Isaacs I, Fuchs C, Schneidman M, Faragian S, Weizman R, Weizman A.
    Am J Psychiatry; 2003 Feb 18; 160(2):297-302. PubMed ID: 12562576
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.
    Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Svensson CK, Koyuncu K, Schjerning O, Oturai PS, Kjaer A, Nielsen J, Holst JJ, Ekstrøm CT, Correll CU, Vilsbøll T, Fink-Jensen A.
    JAMA Psychiatry; 2017 Jul 01; 74(7):719-728. PubMed ID: 28601891
    [Abstract] [Full Text] [Related]

  • 35. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
    Mathus-Vliegen EM, Balance Study Group.
    Eur J Clin Nutr; 2005 Aug 01; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
    [Abstract] [Full Text] [Related]

  • 36. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.
    McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A.
    Am J Psychiatry; 2006 May 01; 163(5):790-9. PubMed ID: 16648318
    [Abstract] [Full Text] [Related]

  • 37. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
    Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM.
    Obes Res; 2000 Sep 01; 8(6):431-7. PubMed ID: 11011909
    [Abstract] [Full Text] [Related]

  • 38. A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain.
    McElroy SL, Winstanley E, Mori N, Martens B, McCoy J, Moeller D, Guerdjikova AI, Keck PE.
    J Clin Psychopharmacol; 2012 Apr 01; 32(2):165-72. PubMed ID: 22367654
    [Abstract] [Full Text] [Related]

  • 39. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO.
    Am J Psychiatry; 2004 Oct 01; 161(10):1837-47. PubMed ID: 15465981
    [Abstract] [Full Text] [Related]

  • 40. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
    Kinon BJ, Basson BR, Gilmore JA, Tollefson GD.
    J Clin Psychiatry; 2001 Feb 01; 62(2):92-100. PubMed ID: 11247108
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.